KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Operating Leases (2019 - 2022)

Palvella Therapeutics (PVLA) has disclosed Operating Leases for 5 consecutive years, with $12.8 million as the latest value for Q2 2023.

  • On a quarterly basis, Operating Leases rose 3.99% to $12.8 million in Q2 2023 year-over-year; TTM through Jun 2023 was $12.8 million, a 3.99% increase, with the full-year FY2022 number at $12.2 million, down 11.54% from a year prior.
  • Operating Leases was $12.8 million for Q2 2023 at Palvella Therapeutics, down from $13.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $16.4 million in Q3 2020 to a low of $11.4 million in Q3 2022.
  • A 5-year average of $14.1 million and a median of $14.4 million in 2021 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: dropped 21.14% in 2022, then rose 3.99% in 2023.
  • Palvella Therapeutics' Operating Leases stood at $15.5 million in 2019, then rose by 2.89% to $15.9 million in 2020, then fell by 13.12% to $13.8 million in 2021, then dropped by 11.54% to $12.2 million in 2022, then rose by 4.76% to $12.8 million in 2023.
  • Per Business Quant, the three most recent readings for PVLA's Operating Leases are $12.8 million (Q2 2023), $13.1 million (Q1 2023), and $12.2 million (Q4 2022).